Suchergebnisse - (Person:"De Meyer, Sandra")

PubPharm (16)

1

Virology analysis in HCV genotype 1-infected patients treated with the combination of simeprevir and TMC647055/ritonavir, with and without ribavirin, and JNJ-56914845

enthalten in: Virology journal | 2017

von Vijgen, L. | Thys, K. | Vandebosch, A. | +3

2

Virological analysis of once-daily and twice-daily darunavir/ritonavir in the ODIN trial of treatment-experienced patients

enthalten in: Antiviral therapy | 2013

von Lathouwers, E. | De La Rosa, G. | Van de Casteele, T. | +4

3

Week 96 efficacy, virology and safety of darunavir/r versus lopinavir/r in treatment-experienced patients in TITAN

enthalten in: Current HIV research | 2012

von Bánhegyi, D. | Katlama, C. | da Cunha, C. | +7

4

Virological characterization of patients failing darunavir/ritonavir or lopinavir/ritonavir treatment in the ARTEMIS study : 96-week analysis

enthalten in: Antiviral therapy | 2011

von Lathouwers, E. | De Meyer, S. | Dierynck, I. | +4

5

In vitro susceptibility and virological outcome to darunavir and lopinavir are independent of HIV type-1 subtype in treatment-naive patients

enthalten in: Antiviral therapy | 2010

von Dierynck, I. | De Meyer, S. | Lathouwers, E. | +5

6

Characterization of virologic failure patients on darunavir/ritonavir in treatment-experienced patients

enthalten in: AIDS (London, England) | 2009

von De Meyer, S. | Lathouwers, E. | Dierynck, I. | +7

7

Efficacy and safety of darunavir/ritonavir in treatment-experienced HIV type-1 patients in the POWER 1, 2 and 3 trials at week 96

enthalten in: Antiviral therapy | 2009

von Arastéh, K. | Yeni, P. | Pozniak, A. | +7

8

Influence of baseline protease inhibitor resistance on the efficacy of darunavir/ritonavir or lopinavir/ritonavir in the TITAN trial

enthalten in: Journal of acquired immune deficiency syndromes (1999) | 2008

von De Meyer, S. | Hill, A. | Picchio, G. | +3

CommentOn: AIDS. 2007 Oct 18;21(16):2245-8. - PMID 18090054

9

Efficacy of once-daily darunavir/ritonavir 800/100 mg in HIV-infected, treatment-experienced patients with no baseline resistance-associated mutations to darunavir

enthalten in: Journal of acquired immune deficiency syndromes (1999) | 2008

von De Meyer, S. | Spinosa-Guzman, S. | Vangeneugden, T. | +2

10

Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naive HIV-1-infected patients at week 48

enthalten in: AIDS (London, England) | 2008

von Ortiz, R. | Dejesus, E. | Khanlou, H. | +9